The ODPRN has conducted multiple studies that have both informed and evaluated the impact of drug policies in Ontario, and more broadly across Canada. This research includes a wide breadth of work ranging from large drug class reviews to specific rapid response projects resulting from decision makers’ pressing initiatives.
Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: A cross-sectional time series analysis
Biologic drugs are compounds derived from living organisms that are important treatment options across a number of medical indications. A biosimilar is a drug that is highly similar and has no clinically meaningful differences to an innovator biologic that has already been authorized for sale, but with a significantly lower price.
The ODPRN used real-world data in Ontario to estimate the number of patients potentially impacted by different biosimilar policy options and the cost implications of these policies. Three people with lived experience using biologics participated on the study team.
Access the full article and associated resources: